Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...

During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...

There are no targeted therapies specifically approved for patients with HER2-ultra-low expression, and approval would move Enhertu up the treatment pathway ahead of chemo. The results reported at ...

Patients with tumours that are HER2-low or HER2-ultralow now have more options to consider with their healthcare team.” In the trial, Enhertu showed a 36% reduction in the risk of disease progression ...

Enhertu is a HER2-directed antibody and topoisomerase ... Study participants with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer who disease had progressed on endocrine therapy ...